Macrophage differentiation and function in atherosclerosis: Opportunities for therapeutic intervention?

Journal of Innate Immunity

Volumn 4, Issue 5-6, 2012, Pages 498-508

  Williams, Howell J ^a   Fisher, Edward A ^a,b   Greaves, David R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Chemokines; Cytokines; Macrophages; Therapy

Indexed keywords

ARTERY RUPTURE; ARTERY THROMBOSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; HEART INFARCTION; HUMAN; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE FUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CYTOKINES; HUMANS; MACROPHAGES; MICE;

EID: 84866029575     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000336618     Document Type: Review

References (81)

1. McGill HC Jr, McMahan CA, Gidding SS: Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 2008; 117:1216-1227. (Pubitemid 351552015)
2. Davies MJ, Thomas A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-1140. (Pubitemid 14135387)
3. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995; 92:657-671.
4. Mallat Z, Taleb S, Ait-Oufella H, Tedgui A: The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 2009; 50(suppl):S364-S369.
5. Mayerl C, Lukasser M, Sedivy R, Niedereg-ger H, Seiler R, Wick G: Atherosclerosis research from past to present-on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Vir-chows Arch 2006; 449: 96-103. (Pubitemid 43988369)
6. Barrett TB, Benditt EP: Sis (platelet-derived growth factor B chain) gene transcript levels are elevated in human atherosclerotic lesions compared to normal artery. Proc Natl Acad Sci USA 1987; 84:1099-1103. (Pubitemid 17031576)
7. Ross R: The pathogenesis of atherosclerosis-an update. N Engl J Med 1986; 314: 488-500.
8. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924. (Pubitemid 19101597)
9. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arte-rioscler Thromb Vasc Biol 1995; 15:551-561.
10. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
11. Williams KJ, Feig JE, Fisher EA: Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 2008; 5:91-102. (Pubitemid 351168064)
12. Steinberg D: Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J Lipid Res 2004; 45:1583-1593.
13. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809. (Pubitemid 23132154)
14. Knowles JW, Maeda N: Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000; 20:2336-2345.
15. Moore KJ, Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-355.
16. Libby P, Ridker PM, Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473:317-325.
17. Passlick B, Flieger D, Ziegler-Heitbrock HW: Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74:2527-2534. (Pubitemid 19286475)
18. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB: Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116:e74-e80.
19. Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, Kourilsky P, Wong SC: Gene expression profiling reveals the defining features of the classical, intermediate, and non-classical human monocyte subsets. Blood 2011; 118:e16-e31.
20. Woollard KJ, Geissmann F: Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77-86.
21. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S: CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113: 963-972.
22. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194. (Pubitemid 46048465)
23. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ: Ly-6Chi monocytes dominate hypercholester-olemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205. (Pubitemid 46048466)
24. van Furth R, Cohn ZA: The origin and kinetics of mononuclear phagocytes. J Exp Med 1968; 128:415-435.
25. Ingersoll MA, Platt AM, Potteaux S, Randolph GJ: Monocyte trafficking in acute and chronic inflammation. Trends Immunol 2011; 32: 470-477.
26. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z: Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and al most abolishes atherosclerosis in hypercho-lesterolemic mice. Circulation 2008; 117: 1649-1657. (Pubitemid 351482605)
27. Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604.
28. Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci 2008; 13: 453-461. (Pubitemid 351599757)
29. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686. (Pubitemid 39457982)
30. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
31. Martinez FO, Gordon S, Locati M, Man-tovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177:7303-7311. (Pubitemid 44715100)
32. Murray PJ, Wynn TA: Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011; 89:557-563.
33. Poston RN, Hussain IF: The immunohisto-chemical heterogeneity of atheroma macro-phages: comparison with lymphoid tissues suggests that recently blood-derived macro-phages can be distinguished from longer-resident cells. J Histochem Cytochem 1993; 41:1503-1512. (Pubitemid 23275252)
34. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6:137-143. (Pubitemid 47189091)
35. Feig JE, Parathath S, Rong JX, Mick SL, Ven-grenyuk Y, Grauer L, Young SG, Fisher EA: Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011; 123:989-998.
36. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G: Macrophage plasticity in experimental atherosclerosis. PLoS One 2010; 5:e8852.
37. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD: Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol 2007; 178:5245-5252. (Pubitemid 46595309)
38. Brocheriou I, Maouche S, Durand H, Braunersreuther V, Le Naour G, Gratchev A, Koskas F, Mach F, Kzhyshkowska J, Ninio E: Antagonistic regulation of macrophage pheno-type by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis 2011; 214: 316-324.
39. Plenz G, Reichenberg S, Koenig C, Rauterberg J, Deng MC, Baba HA, Robenek H: Granulocyte-macrophage colony-stimulating factor (GM-CSF) modulates the expression of type VIII collagen mRNA in vascular smooth muscle cells and both are codistributed during atherogenesis. Arterioscler Thromb Vasc Biol 1999; 19: 1658-1668. (Pubitemid 29323824)
40. Filonzi EL, Zoellner H, Stanton H, Hamilton JA: Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. At herosclerosis 1993; 99: 241-252. (Pubitemid 23130295)
41. Hamilton JA: Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544. (Pubitemid 351913679)
42. Stojakovic M, Krzesz R, Wagner AH, Hecker M: CD154-stimulated GM-CSF release by vascular smooth muscle cells elicits mono-cyte activation-role in atherogenesis. J Mol Med (Berl) 2007; 85:1229-1238. (Pubitemid 47622220)
43. Liao F, Berliner JA, Mehrabian M, Navab M, Demer LL, Lusis AJ, Fogelman AM: Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest 1991; 87: 2253-2257.
44. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G: Macrophage activations witching: an asset for the resolution of inflammation. Clin Exp Immunol 2005; 142:481-489. (Pubitemid 41719844)
45. Kleemann R, Zadelaar S, Kooistra T: Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
46. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
47. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stim-ulating cytokines. Atherosclerosis 1999; 145: 33-43. (Pubitemid 29292698)
48. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH: T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci USA 2005; 102:1596.
49. George J, Shoenfeld Y, Gilburd B, Afek A, Shaish A, Harats D: Requisite role for inter-leukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Myco-bacterium tuberculosis. Circ Res 2000; 86: 1203-1210. (Pubitemid 30436659)
50. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzk i C, Jude B, Staels B: Human at hero-sclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ Res 2011; 108:985-995.
51. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE: Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 10:1284-1288.
52. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR: Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007; 117: 3900-3908. (Pubitemid 350224099)
53. Gallardo-Soler A, Gomez-Nieto C, Campo ML, Marathe C, Tontonoz P, Castrillo A, Corraliza I: Arginase I induction by modified lipoproteins in macrophages: a peroxi-some proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Mol Endocrinol 2008; 22: 1394-1402. (Pubitemid 351786999)
54. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, Kuriakose G, Fisher EA, Marks AR, Ron D, Tabas I: The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macro-phages. Nat Cell Biol 2003; 5:781-792. (Pubitemid 37087166)
55. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, Elliott MR, Gruber F, Han J, Chen W, Kensler T, Ravichandran KS, Isakson BE, Wamhoff BR, Leitinger N: Identification of a novel macrophage pheno-type that develops in response to atherogen-ic phospholipids via Nrf2. Circ Res 2010; 107: 737-746.
56. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C, Cantley LG: Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22:317-326.
57. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS: Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008; 172: 1112-1126. (Pubitemid 351520007)
58. Gleissner CA, Shaked I, Erbel C, Böckler D, Katus HA, Ley K: CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res 2009; 106:203-211.
59. Skjot-Arkil H, Barascuk N, Register T, Kars-dal MA: Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers. Assay Drug Dev Technol 2010; 8:542-552.
60. Virmani R, Burke AP, Kolodgie FD, Farb A: Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002; 15: 439-446. (Pubitemid 35387383)
61. Boyle JJ, Weissberg PL, Bennett MR: Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apop-tosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003; 23: 1553-1558. (Pubitemid 37108197)
62. Flynn PD, Byrne CD, Baglin TP, Weissberg PL, Bennett MR: Thrombin generation by apoptotic vascular smooth muscle cells. Blood 1997; 89:4378-4384. (Pubitemid 27260247)
63. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, Krane SM, Whittaker P, Aikawa M: Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005; 112: 2708-2715. (Pubitemid 41532609)
64. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L: Plasma concentrations and genetic variation of matrix metalloprotein-ase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585. (Pubitemid 36397324)
65. Kalela A, Laaksonen R, Lehtimaki T, Koivu TA, Hoyhtya M, Janatuinen T, Pollanen P, Vesalainen R, Saikku P, Knuuti J, Nikkari ST: Effect of pravastatin in mildly hypercholes-terolemic young men on serum matrix metalloproteinases. Am J Cardiol 2001; 88:173-175, A6. (Pubitemid 32607707)
66. Johnson JL: Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardio-vasc Ther 2007; 5:265-282. (Pubitemid 46488141)
67. Tabas I: The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ Res 2010; 107: 839-850.
68. Myoishi M, Hao H, Minamino T, Watanabe K, Nishihira K, Hatakeyama K, Asada Y, Okada K, Ishibashi-Ueda H, Gabbiani G, Bochaton-Piallat ML, Mochizuki N, Kitakaze M: Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 2007; 116:1226-1233. (Pubitemid 47517533)
69. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, Rayner K, Moore K, Garabedian M, Fisher EA: HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque mono-cyte-derived cells. Proc Natl Acad Sci USA 2011; 108: 7166-7171.
70. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA: Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006; 103: 3781-3786. (Pubitemid 43376632)
71. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ, Sorci-Thomas MG, Randolph GJ: Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/-mice during disease regression. J Clin Invest 2011; 121:2025-2036.
72. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, Moore KJ, Kinane TB: Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 14729-14734. (Pubitemid 41457124)
73. Tsou CL, Peters W, Si Y, Slaymaker S, Asla-nian AM, Weisberg SP, Mack M, Charo IF: Critical roles for CCR2 and MCP-3 in mono-cyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007; 117:902-909. (Pubitemid 46556746)
74. Bursill CA, Choudhury R P, Ali Z, Greaves DR, Channon KM: Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 2004; 110: 2460-2466. (Pubitemid 39407354)
75. White GE, McNeill E, Christou I, Channon KM, Greaves DR: Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade. Mol Pharmacol 2011; 80:328-336.
76. Wang AZ, Langer RS, Farokhzad OC: Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-198.
77. Owen DR, Lindsay AC, Choudhury R P, Fayad ZA: Imaging of atherosclerosis. Annu Rev Med 2011; 62: 25-40.
78. Wan JB, Huang LL, Rong R, Tan R, Wang J, Kang JX: Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation. Arterioscler Thromb Vasc Biol 2010; 30: 2487-2494.
79. Ariel A, Serhan CN: Resolvins and protec-tins in the termination program of acute inflammation. Trends Immunol 2007; 28:176-183. (Pubitemid 46467520)
80. Toomey S, Harhen B, Roche HM, Fitzgerald D, Belton O: Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 2006; 187:40-49. (Pubitemid 43817000)
81. Hansson GK, Hermansson A: The immune system in atherosclerosis. Nat Immunol 2011; 12:204-212.